- Inaugural Address: Mr. KT Rama Rao, Hon’ble Minister of Industries & Commerce, Government of Telangana
- Presentation of Genome Valley Excellence Award
- Dr. Drew Weissman (TIME Magazine 2021's "Heroes of the Year", Breakthrough Prize in Life Sciences 2022 and Lasker-DeBakey 2021 awardee for development of effective mRNA Covid-19 vaccines and Professor of Medicine, University of Pennsylvania, USA)
- Keynote Address by Dr. Drew Weissman
- Fireside chat between Dr. Drew Weissman and Dr. Sangita Reddy, Managing Director, Apollo Hospitals
Challenges, successes and what next?
The COVID-19 pandemic brought to fore the urgency to strengthen the healthcare delivery system globally. It further highlighted how equitable access to care is critical for economic growth and security of any nation. The last two years saw several new experiments globally across the entire value chain of managing healthcare delivery – some of these were successful, while others failed. But all these experiments have given us immense learning. This session is to discuss:
- Our successes (what we did well) and challenges (what we could have done better), and how we can benefit from the learnings to shape the future of healthcare
- Future healthcare challenges, and how can we prepare for it today
- Dr. Soumya Swaminathan, Chief Scientist, WHO
- Mr. Amitabh Kant, CEO, NITI Aayog
- Dr. Rajesh S Gokhale, Secretary, Dept. of Biotechnology, Government of India
- Dr. Peter Piot, EU Chief Scientific Advisor Epidemics, Handa Professor of Global Health, London School of Hygiene & Tropical Medicine
- Dr. Krishna Ella, Managing Director, Bharat Biotech International Ltd.
- Ms. Mahima Datla, Managing Director, Biological E Ltd.
- Dr. Gagandeep Kang, Virologist and Professor, Dept. of Gastrointestinal Sciences, CMC Vellore
‘Digital’ and ‘data analytics’ adoption has accelerated across all industries in the last few years, especially during COVID – and pharma / healthcare is no exception. Shift towards patient centricity, prevention & wellness, and anywhere & anytime healthcare delivery has created new opportunities to reimagine the entire patient journey. Data analytics and new technologies such as artificial intelligence, blockchain, sensor, etc. are reshaping the entire product value chain (innovation to medicine access). Many pharma and tech companies globally are coming up with such new solutions. This session focuses on:
- How traditional Life Sciences companies are leveraging Technology vs. how Technology companies are approaching Healthcare
- Pharma-tech collaborations to build on each other’s strengths and launch truly innovative solutions
- Dr. David Rhew, Global Chief Medical Officer & VP of Healthcare, Microsoft, USA
- Mr. Davidek Herron, Global Head of Digital, Roche Group, Switzerland
- Mr. Ashwini Mathur, Head Clinical Technology and Innovation, Novartis, Ireland
- Mr. Jayesh Ranjan IAS, Principal Secretary, Industries & Commerce Dept., Government of Telangana
- Mr. Geoff Martha, CEO & Chairman - Board of Directors, Medtronic
- Global trends in the Medtech Sector
- Role India and Asia can play in the global efforts to accelerate medtech growth
- How to drive innovation and role of Tech
- India has been strong in Information Technology (IT). How can India leverage its IT strength in the MedTech and HealthTech industry (e.g., clinical decision support tools, virtual monitoring, chronic disease management platforms, etc.). What are startups doing in this space? What are future challenges and opportunities?
- What policy interventions can help India foray into complex and innovative medical devices?
Challenges and strategic opportunities:
- Ms. Teena Thacker, Journalist, The Economic Times
- Mr. Bill Gates (Co-chair, Bill & Melinda Gates Foundation), and Mr. KT Rama Rao, Hon’ble Minister of Industries & Commerce, Government of Telangana
- How to identify ways to encourage innovation in Indian biotech Pharma
- What is the mantra to encourage innovation
- How will the innovation progress in next 5 years
- Dr. Ashwini Nangia, Professor, University of Hyderabad ad
- Dr. Vinay Nandicoori, Director, CSIR-CCMB
- Dr. Satakarni Makkapati, President & Head, Biologics, Aurobindo Pharma
- Dr. Gagandeep Kang, CMC Vellore (Former Director of THSTI)
- Dr. Girish Krishnamurthy, CEO TATA Medical and Diagnostics Ltd.
- Dr. Uday Saxena, Co-founder and CEO, ReaGene Innovations
- How industry can achieve its ambition of now moving from ‘volume only’ to ‘value+volume’
- Learnings from R&D best practices for COVID drugs and vaccines (e.g., virtualization of clinical trials, parallel processes, speedy approvals, collaborations) and recent successes (e.g. Covaxin)
- Plan for future innovation (innovating new tech platforms), role of academia and developing the ecosystem
- Funding (public, private, and public-private-partnership models) and infrastructure availability: private equity, where is the capital flowing (what do the investors value)
- Robust Intellectual Protection and increased collaboration with the global firms (case study)
- Moving from Make in India to Discover in India
- Dr. S Chandrashekhar, Secretary, Dept. of Science & Technology, Government of India
- Mr. N. Yuvaraj, Joint Secretary (Policy, Medical Device, Pharma Bureau), Dept. of Pharmaceuticals,Government of India
- Ms. Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group
- Mr. Satish Reddy, Chairman, Dr. Reddy’s Laboratories
- Mr. Sharvil Patel, Managing Director, Zydus Cadila
- Mr. Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines Ltd.
- Ms. Ekta Batra, Anchor & Associate Editor Research,CNBC-TV18
- Mr. Alex Gorsky, Executive Chairman, Johnson & Johnson
- Fireside chat with Mr. Alex Gorsky, Dr. Ajit Shetty (Former Chairman, Janssen Pharmaceutica & Chairman, International Advisory Board, BioAsia) and Mr. Shakthi Nagappan, Director (Life Sciences and Pharma, Govt. of Telangana & CEO, BioAsia)
Becoming preferred/trusted global drug suppliers
Deliberation on some important elements to achieve global leadership:
- It is first important to strengthen the foundation and then shift to manufacturing novel medicines: where have we reached in our journey of achieving self-reliance in API manufacturing ?
- how can we build the capabilities (skilled human resource and technological advancement) to manufacture complex novel drugs at scale (e.g., complex biologics, cell & gene therapies, etc.), and the COVID drugs from the global MNCs
- What have we done to increase focus on drug quality?
- What are the real issues and how can we address those (e.g., infrastructure and people/training/culture investments to establish right quality frameworks, and establish quality by design?)
- Did India benefit from China de-risking? What did we do well and what we could do better? Can India be considered as a second threat to countries globally (like China)? How can we de-risk on that aspect?
- What best practices emerged during pandemic (demand planning, nimbleness, technology enhancements, etc.)?
- How can suppliers, customer, vendors, pharma companies share information and collaborate better? What can we learn from the collaborations during the pandemic?
- A lot is going on in the US market at the moment, e.g., the build back better act. What can be the implications for Indian generic companies and how do we keep the supply chain alive?
- Mr. Ronald T. Piervincenzi, CEO, United States Pharmacopeia
- Mr. Anil Kumar Jain, CEO API Business, Sun Pharma
- Mr. Sanjay Chaturvedi, CEO IOL Chemicals and Pharmaceuticals
- Mr. Sandeep Narang,Associate Vice President - Head Global Supply Chain Planning, Alkem Laboratories Ltd
- Mr. Saikat Ghosh, Associate Partner, EY
- Ms. Anju Ghangurde, Executive Editor (APAC), Scrip Intelligence (Informa)
- Adapting to the pandemic: Ensuring safe, effective and high-quality drugs availability to the public, specially during and post pandemic
- Challenges faced and changes made by regulatory authorities to accommodate for industry disruption and how will it impact the industry
- Harmonization in the approaches across the world’s regulatory authorities
- Preparedness on the crisis management in future
- Are we prepared for the future of virtual audits?
- Dr. S.Eswara Reddy, Joint Drugs Controller (India), Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, Government of India
- Dr. Phil Nguyen, International Relations Specialist, US Food and Drug Administration
Mr. Paul Polman, Business Leader, Campaigner and Co-author of “Net Positive"
A former CEO of Unilever, Paul is also the Chairman of the International Chamber of Commerce, Chair of the B Team and Vice-Chair of the UN Global Compact. Paul previously served as Chairman of the World Business Council for Sustainable Development.
Moving up the value chain for the next wave of growth / Leading into a resilient future
All industry leaders agree on the importance of innovation-led future. Indeed, after establishing a strong presence in the global generics market, and getting recognized as the pharmacy of the world, the next wave of growth for Indian Pharma Industry will be led by truly innovative drugs. The session will focus on:
- Key growth drivers for Indian Pharma Industry and the potential opportunity
- Imperatives for the industry and the entire ecosystem today to achieve the ambition
- Mr. Ajay Piramal, Chairman, Piramal Group
- Mr. Dilip Shanghvi, Managing Director, Sun Pharma
- Mr. Pankaj Patel, Chairman and Managing Director, Zydus Cadila
- Mr. GV Prasad, Co-Chairman and Managing Director, Dr. Reddy’s Laboratories
- Ms. Shereen Bhan, Managing Editor, CNBC-TV18
- Chief Guest: Mr. Jayesh Ranjan IAS, Principal Secretary, Industries & Commerce Dept., Government of Telangana
- Guest of Honour : Prof.D.Balasubramanian, Director of Research Emeritus, LV Prasad Eye Institute
- Presentation of Dr. B.S.Bajaj Memorial FABA Special Award 2022 to Ms. Mahima Datla, Managing Director, Biological E Ltd.
- Presentation of FABA Lifetime Achievement Award to Mr. BP Acharya IAS,Advisor, ICMR-National Animal Resource Facility for Biomedical Research